Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/1999 First Published: 7/1/1998


1.		Phase III Randomized Study of IDEC-Y2B8 Radioimmunotherapy Versus Rituximab Immunotherapy for Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				Pharmaceutical / Industry				IDEC-106-04 MAYO-977802

Last Modified: 12/1/1999 First Published: 4/1/1999


2.		Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				IDEC-106-06 MAYO-987804, UCLA-9808026


3.		Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				60 and over				Pharmaceutical / Industry				307940/106-20 NCT00322218

Last Modified: 1/1/2000 First Published: 11/1/1999


4.		Phase II Study of Ibritumomab Tiuxetan (IDEC-Y2B8) Radioimmunotherapy in Patients with Relapsed or Refractory, Low Grade or B-Cell, Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-9804024 IDEC-106-05, NCI-G99-1614

Last Modified: 6/1/2002 First Published: 5/1/2000


5.		Phase II Study of Rituximab and Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Relapsed or Refractory, Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UAB-9930 GUMC-00095, IDEC-106-98, NCI-G00-1731, NCT00005592


6.		Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				UPCI #03-005 NCT00177554


7.		Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 70				Other				GELTAMO-LCM-04-02 NCT00505232


8.		Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				HO04405 NCT00582166

Select All on One Page